AG
CLVS

Advisor Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Advisor Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$39K Buy
3,765
+2,474
+192% +$18K ﹤0.01% 3586
2019
Q3 		$4K Buy
1,291
+676
+110% +$5.47K ﹤0.01% 4787
2019
Q2 		$9K Buy
615
+80
+15% +$1.45K ﹤0.01% 4444
2019
Q1 		$13K Hold
535
– – ﹤0.01% 4243
2018
Q4 		$9K Buy
535
+110
+26% +$2.25K ﹤0.01% 4279
2018
Q3 		$13K Sell
425
-328
-44% -$12.7K ﹤0.01% 4145
2018
Q2 		$35K Sell
753
-50
-6% -$2.43K ﹤0.01% 3375
2018
Q1 		$42K Sell
803
-330
-29% -$19.3K ﹤0.01% 3210
2017
Q4 		$78K Sell
1,133
-8
-0.7% -$559 ﹤0.01% 2764
2017
Q3 		$94K Buy
1,141
+274
+32% +$21.7K ﹤0.01% 2464
2017
Q2 		$82K Buy
867
+157
+22% +$9.61K ﹤0.01% 2475
2017
Q1 		$46K Sell
710
-240
-25% -$14.6K ﹤0.01% 2788
2016
Q4 		$42K Sell
950
-443
-32% -$15.6K ﹤0.01% 2750
2016
Q3 		$50K Buy
1,393
+1,221
+710% +$26.2K ﹤0.01% 2551
2016
Q2 		$2K Buy
+172
New +$2.51K ﹤0.01% 4142

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Advisor Group's CLVS Position: Q4 2019 in Review

Advisor Group increased its Clovis Oncology, Inc. (CLVS) stake by 192% in Q4 2019, buying an estimated $18K and bringing the position to 3,765 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.

Advisor Group first reported a position in CLVS in Q2 2016 and has held it in 15 quarters since. The position peaked at $94K in Q3 2017. 147 funds tracked by Wall St. Rank hold CLVS as of Q4 2019.

  • Advisor Group held 3,765 shares of Clovis Oncology, Inc. worth $39K as of Q4 2019.
  • Advisor Group bought 2,474 Clovis Oncology, Inc. shares in Q4 2019, an estimated $18K.
  • Clovis Oncology, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3586 holding.
  • Advisor Group first reported a position in Clovis Oncology, Inc. in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Clovis Oncology, Inc. position peaked at $94K in Q3 2017.
  • 147 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.